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Tuberous sclerosis complex (TSC) is a familial hamartoma syndrome in which renal involvement is common and,
at times, life threatening. We have investigated the potential effect of a non-TSC gene on renal disease in a cohort
of 172 TSC patients with TSC2 mutations. Patients were genotyped for an interferon-g (IFN-g) microsatellite
polymorphism, within intron 1, for which one common allele (allele 2, with 12 CA repeats) has been shown to
have a higher expression of IFN-g. A x2 analysis was used to examine the association between IFN-g allele 2 and
the development of kidney angiomyolipomas (KAMLs) in this TSC2 cohort. Because of the age-dependent devel-
opment of KAMLs in TSC, we initially focused on the 127 patients who were 15 years old. Additional subgroup
analyses were done to investigate the influence of age and gender. The transmission/disequilibrium test (TDT) was
also performed in a subset of this cohort (46 probands) for whom parent and/or sibling samples were available
for analysis. Both x2 analysis and TDT suggested an association between IFN-g allele 2 and the absence of KAMLs
in patients who have known TSC2 mutations. Among the 127 patients who were 15 years old, KAMLs were
present in 95 (75%) and were absent in 32 (25%). In the group with KAML present, the frequency of IFN-g allele
2 was 56%; in the group with KAML absent, the frequency of IFN-g allele 2 was significantly higher, at 78%
( , by x2 analysis). The family-based TDT analysis gave similar results, with a TDT statistic (TDT 2Pp .02 x p
) corresponding to a P value of .02. Subgroup analyses show that both age and gender may influence the5.45
impact of this association. Although these results should be replicated in other populations with TSC, the present
study suggests that modifier genes play a role in the variable expression of TSC and also suggests a potential therapy
for KAMLs in patients with TSC.
Introduction
Tuberous sclerosis complex (TSC [MIM 605284 and
MIM 191092]) is a multisystem familial tumor syn-
drome with autosomal dominant inheritance. Two caus-
ative genes (TSC1 and TSC2) have been identified (Eu-
ropean Chromosome 16 Tuberous Sclerosis Consortium
1993; van Slegtenhorst et al. 1997). The tumors that
develop are hamartomas, and the organs most com-
monly affected are the brain, skin, and kidneys (Kwiat-
kowski and Short 1994; Gomez et al. 1999; Cheadle et
al. 2000). Although there is high penetrance, the ex-
pression is variable even among individuals with iden-
tical mutations (Smalley et al. 1994; Dabora et al. 2001).
There is a wide range of severity of TSC manifestations,
Received April 25, 2002; accepted for publication June 26, 2002;
electronically published August 21, 2002.
Address for correspondence and reprints: Dr. Sandra L. Dabora,
Division of Hematology, Brigham and Women’s Hospital, 221 Long-
wood Avenue, LMRC 301, Boston, MA 02115. E-mail: sdabora@
rics.bwh.harvard.edu
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7104-0006$15.00
with some individuals so severely affected they are un-
able to care for themselves, while others are only mildly
affected and may not be aware of their diagnosis until
adulthood. Since many TSC lesions result from a two-
hit mechanism, some of the variability is likely due to
the stochastic nature of second-hit events (Henske et al.
1996, 1997; Niida et al. 2001). It is also possible that
environmental exposures or modifier genes influence se-
verity of disease in TSC.
Renal disease in TSC is a source of significant mor-
bidity and mortality, since 17%–25% develop cysts and
55%–80% develop kidney angiomyolipomas (KAMLs)
(Ewalt et al. 1998; Gomez et al. 1999; Jozwiak et al.
2000; Dabora et al. 2001). Transgenic mice and Eker
rats in which the Tsc2 gene had been inactivated also
developed significant renal disease in the form of kidney
cystadenomas and carcinomas (Yeung et al. 1994; Ko-
bayashi et al. 1999; Onda et al. 1999). Although the
lesions are not identical to the cysts and angiomyolipo-
mas that develop in humans with TSC, the frequency
of tumors is similar. Strain differences observed in the
mouse model of TSC2 suggest that modifier genes may
influence severity of certain lesions (Onda et al. 1999).
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Human interferon-g (IFN-g) is a homodimeric 34-kD
peptide secreted by T lymphocytes and natural killer
cells. It plays an important role in the coordinated reg-
ulation of expression of the immune response via the
stimulation or repression of key genes (Farrar and
Schreiber 1993). Human IFN-g is encoded by a single
gene on chromosome 12q24.1 and contains four exons
with three introns. The first intron contains a CA mi-
crosatellite repeat that is highly polymorphic, with up
to six alleles. Allele 2, with 12 CA repeats, has been
shown to be associated with high levels of IFN-g pro-
duction in vitro (Pravica et al. 1999), and this may be
due to its association with a nearby SNP within a pu-
tative NF-kappa B binding site (Pravica et al. 2000).
This allele has been associated with higher or lower risk
of a variety of diseases, including rheumatoid arthritis,
allograft fibrosis in lung-transplant recipients, and acute
graft-versus-host disease in bone-marrow–transplant re-
cipients (Awad et al. 1999; Khani-Hanjani et al. 2000;
Cavet et al. 2001).
Because IFN-g has been shown to be a useful medi-
ator of tumor regression in animal models of kidney
tumors (Lee et al. 2000; Becker et al. 2001) and because
there is a known high-expressing allele of IFN-g in hu-
mans, we examined the relationship between the IFN-
g genotype and the severity of renal disease in patients
with TSC who had TSC2 mutations.
Subjects and Methods
Patients and TSC Mutation Analysis
We studied 172 patients with TSC for whom we have
identified TSC2 mutations and for whom we have data
on renal phenotype; 121 have been described elsewhere
(Dabora et al. 2001), and 51 are patients with new mu-
tations found by similar methods. We included all avail-
able patients with both a known pathogenic TSC2 mu-
tation and clinical information on the presence or
absence of KAMLs. Most (150) patients were referred
by pediatric neurology practices (80 from Warsaw, 49
from Cincinnati, and 21 from Boston), and the remain-
der (22) came from mail requests. Informed consent was
obtained from all participants, and this study was ap-
proved by the institutional review boards at all partic-
ipating institutions. The presence or absence of KAMLs
was determined by ultrasound, computed tomography
(CT), or magnetic-resonance imaging (MRI) and was
graded on a scale of 0–3, as described elsewhere (Dabora
et al. 2001). Grade 0 indicates that no KAMLs were
detected; grade 1 indicates that one or more KAMLs !1
cm were detected; grade 2 indicates that one or more
KAMLs 11 cm but !4 cm were detected; and grade 3
indicates that one or more KAMLs 14 cm were detected.
The age used for each patient in this analysis was the
age of the patient at most recent complete clinical eval-
uation. Kidney imaging was performed within 1 year of
this age in most (132/172 [77%]) patients, within 2 years
in 16/172 (9%) patients, and within 3 years in 11/172
(6%) and could not be confirmed in 13/172 (8%).
The method of kidney imaging was determined by
medical record review in 169/172 (98%) patients, and
consisted of ultrasound in nearly all of these (162/169
[96%]); in 16/162 (10%), CT or MRI was done in ad-
dition to ultrasound. In the remaining seven patients,
kidneys were imaged by CT (five patients) or MRI (two
patients) scan. Of the 22 patients that had CT or MRI
scans, most (21/22) had grade 2 or 3 KAMLs, and 1
had grade 1 KAMLs. Kidney-imaging data was collected
prior to IFN-g genotyping in all cases. Most (129/172
[75%]) of the kidney-imaging studies were read by ra-
diologists at centers with specific expertise in the care
of patients with TSC.
IFN-g Genotyping
Genotyping for the intron 1 CA repeat of the IFN-g
gene was performed by modification of the fluorescent
PCR method described by Khani-Hanajani et al. (2000).
The following primers were obtained from Research Ge-
netics: forward, 5′-6-FAM AGACATTCACAATTGAT-
TTTATTCTTAC-3′, and reverse, 5′-GTGTCTTCCTT-
CCTGTAGGGTATTATTATACG-3′. The underlined
portion of the reverse primer is a 7-bp clamp that was
added to reduce stutter artifact. PCR was performed
using AmpliTaqR Gold (Perkin Elmer); 20-ml reactions
were used with 10–50 ng of genomic DNA, 0.5 mM of
each primer, 10 mM deoxyribonucleoside triphosphates,
0.2 ml of AmplitaqR gold (1 U), and the manufacturer’s
recommended buffers. PCR cycling was performed on
an MJ Research PTC-100 thermal cycler, at 95C for 12
min, followed by 35 cycles at 94C for 30 s; 57C for
30 s, for annealing; 72C for 45 s, for extension; and a
final extension step at 72C for 4 min. The 6-
FAM–labeled PCR products were run on an ABI 3100
capillary sequencer with HD 400 as a size standard.
Genescan 3.7 software (ABI) was used to determine the
size of the amplicons, to assign the IFN-g alleles present
in each sample, and was confirmed by manual review.
Statistical Analysis
x2-, Fisher-, and t-test analyses were done with Stat-
view 5.0 software. The x2 or Fisher test was used for
nominal variables, and the one-tailed t test was used for
quantitative variables. The transmission/disequilibrium
test (TDT) statistic was calculated, as described by Spiel-
man et al. (1993), as follows: TDT 2 2x p (b c) /(b
, where TDT x2 is used to calculate the P value fromc)
a x2 table with 1 df, b represents the number of times
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Table 1
IFN-g Allele Frequencies in TSC2 Patients 15 Years Old
All
KAML
Absent
KAML
Present P
N (%) 127 32 (25) 95 (75)
Male (%) 58 (46) 15 (47) 43 (45)
Female (%) 69 (54) 17 (53) 52 (55)
Mean age (range) [in years] 15.2 (6–49) 14.1 (6–34) 15.6 (6–49) .37a
No. with allele 2 present (female/male) 78 (40/38) 25 (12/13) 53 (28/25) .02b
No. with allele 2 absent (female/male) 49 (29/20) 7 (5/2) 42 (24/18)
% with allele 2 present 61 78 56
% with allele 2 absent 39 22 44
a By t test; result not significant.
b By x2 analysis.
Table 2
KAML Frequency in the Presence or Absence of IFN-g Allele 2 in
TSC2 Patients 15 Years Old
NO. (%) WITH IFN-g GENOTYPE
2,2 or 2,X X,X
KAML present 53 (68) 42 (86)
KAML absent 25 (32) 7 (14)
Overall 78 49
NOTE.—Allele X represents any allele other than 2.
that the allele of interest is transmitted, and c represents
the number of times that it is not transmitted.
Results
IFN-g Allele 2 Is Associated with Absence of KAMLs in
TSC2 Patients 15 Years Old
We studied 172 patients with known TSC2mutations
and for whom clinical data on the presence or absence
of KAMLs were available, to investigate the association
of IFN-g allele 2 with the development of KAMLs in
TSC2 patients. Because of the age-dependent develop-
ment of KAMLs in TSC (Kwiatkowski and Short 1994;
Ewalt et al. 1998; Jozwiak et al. 2000), we initially con-
sidered only the 127 individuals who were 15 years old.
Mutation analysis was performed as described elsewhere
(Dabora et al. 2001), and KAMLs were detected by renal
ultrasound, CT, or MRI scan. As shown in table 1, there
were 95 (75%) TSC2 patients with KAMLs present and
32 (25%) TSC2 patients with KAMLs absent in this
cohort. This includes 44/59 (75%) from Warsaw, 30/35
(86%) from Cincinnati, 11/13 (85%) from Boston, and
10/20 (50%) from mail requests. Gender and age dis-
tribution were similar in the KAML-present and KAML-
absent groups. However, the frequency of IFN-g allele
2 was 78% (25/32) in the KAML-absent group and 56%
(53/95) in the KAML-present group. This difference is
statistically significant ( , by x2 analysis). OurPp .02
data do not demonstrate a trend of lower frequency of
IFN-g allele 2 in patients with higher-grade KAMLs, but
this analysis is limited by relatively small numbers of
patients with KAMLs of grades 2 and 3. The frequency
of IFN-g allele 2 for KAMLs of grades 1–3 was 57%
(31/54 patients) for grade 1, 42% (10/24 patients) for
grade 2, and 71% (12/17 patients) for grade 3. Viewed
from the perspective of allelic risk, 68% of TSC2 pa-
tients with allele 2 have KAMLs, and 32% do not. In
contrast, 86% of TSC2 patients without allele 2 have
KAML, and 14% do not. Thus, TSC2 patients with IFN-
g allele 2 are approximately twice as likely to be free
of KAMLs as are TSC2 patients without IFN-g allele 2
(table 2).
IFN-g Allele and Genotype Frequencies
The allele and genotype frequencies in this study and
those reported in the literature (Perrey et al. 1998) are
shown in table 3. Although up to six alleles for the CA
repeat within intron 1 of IFN-g have been reported, two
common alleles (2 and 3) account for 85%–95% of
alleles in several studies (Perrey et al. 1998; Awad et al.
1999; Pravica et al. 1999; Khani-Hanjani et al. 2000).
In the cohort of 127 patients that we studied, alleles 2
and 3 account for 88% of the alleles. Although the fre-
quencies of alleles in this entire cohort are similar to
those in other studies, the frequency of allele 2 in the
KAML-present group (36%) was lower than in the
KAML-absent group (50%). The results were more
striking when genotype frequencies were compared (ta-
ble 3 and fig. 1). In control cohorts that have been de-
scribed elsewhere, the frequency of a genotype that con-
tains at least one allele 2 is 75%. We found that,
although the frequency of a genotype that contains allele
2 in the entire cohort was fairly close to this, at 61.4%,
there was a difference in this frequency when the KAML-
present group was compared with the KAML-absent
group, with a significantly lower frequency of allele 2
in the KAML-present group (56% vs. 78%; ),Pp .02
as stated above.
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Figure 1 IFN-g genotype frequencies in TSC2 patients 15 years
old. The KAML-absent group ( ) is denoted by blackened bars,np 32
and the KAML-present group ( ) is denoted by unblackenednp 95
bars. Allele X refers to any allele other than 2.
Table 3
IFN-g Allele and Genotype Frequencies in TSC2 Patients 15 Years Old
FREQUENCY IN
(%)
KAML Absent
(n p 32)
KAML Present
(n p 95)
Entire Cohort
(n p 127)
Perrey et al. 1998
(n p 164)
Allele:
2 50.0 36.3 39.8 48.2
3 42.2 50.5 48.4 42.7
4 6.3 6.8 6.7 4.3
5 1.6 5.8 4.7 4.9
6 .0 .5 .4 .0
Genotype:
2,2 21.9 16.8 18.1 20.7
2,3 46.9 29.5 33.9 47.0
2,4 6.3 5.3 5.5 3.0
2,5 3.1 4.2 3.9 4.3
3,3 15.6 27.4 24.4 14.6
3,4 .0 8.4 6.3 4.3
3,5 3.1 7.4 6.3 5.5
3,6 .0 1.1 .8 .0
4,4 3.1 .0 .8 .6
2,2 or 2,Xa 78.1 55.8 61.4 75.0
X,X 21.9 44.2 38.6 25.0
NOTE.—Allele X represents any allele other than 2.
a All genotypes containing allele 2.
Similar Spectrum of TSC2 Mutation Types
across Subgroups
We also considered the possibility that the type of
TSC2 mutation might influence the development of
KAMLs. Although there is some variation in the fre-
quency of mutation type in the KAML-present versus
the KAML-absent groups (table 4), it was not dramatic.
Moreover, when the frequency of all mutations predicted
to cause premature truncation (splice, nonsense, frame-
shift insertions or deletions, and larger rearrangements)
versus those predicted to change one or a few amino
acids (missense and in-frame insertions or deletions),
there is no difference in the KAML-present group versus
the KAML-absent group (table 4).
Age Dependence of IFN-g Allele 2 and KAML
Association
To investigate the possibility that age influences the
association between IFN-g allele 2 and the absence of
KAMLs in TSC2, we did additional subset analyses on
different age groups in the cohort that we studied (table
5). We divided the cohort into three age groups: 1–5-
year-olds, 6–20-year-olds, and 21–49-year-olds. We ob-
served an association between the IFN-g allele 2 and the
absence of KAMLs in the 6–20-year-old group (Pp
, by x2 analysis) but not in the other age groups. We.02
also observed a puzzling result in the 1–5-year-olds. Al-
though the 1–5-year-olds have an expected low rate of
KAMLs (27%), the frequency of IFN-g allele 2 in the
1–5-year-old group with KAMLs present (12 patients)
is unexpectedly high (92%). Our age-subgroup data sug-
gest that the association between IFN-g allele 2 and the
absence of KAMLs is strongest in 6–20-year-olds. The
high frequency of IFN-g allele 2 in the 1–5-year-olds
with KAMLs present is discussed below.
Because exclusion of the 1–5-year-old group with
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Table 4
TSC2 Mutation Spectrum in KAML and IFN-g Allele
Subgroups in TSC2 Patients 15 Years Old
MUTATION TYPE(S)
NO. (%) IN SUBGROUP
KAML Present KAML Absent
In-frame deletion 7 (7) 2 (6)
In-frame insertion 2 (2) 0
Missense 16 (17) 6 (19)
Frameshift deletion 8 (8) 7 (22)
Frameshift insertion 9 (9) 2 (6)
Nonsense 29 (31) 3 (9)
Splice 17 (18) 7 (22)
Large deletion 7 (7) 3 (9)
Duplication 0 2 (6)
Overall 95 32
IF-I, IF-D, missensea 25 (26) 8 (25)
Truncatingb 70 (74) 24 (75)
a In-frame insertion, deletion, or missense.
b Nonsense, splice, frameshift, or large deletion/
duplication.
Table 5
Distribution of KAMLs, Gender, and Allele 2 in Different Age Subgroups of TSC2 Patients
SUBGROUPS
BY AGE
(IN YEARS)
NO.
TOTAL
%
FEMALE
% WITH KAMLS PRESENT
NO. (% WITH ALLELE 2
PRESENT) AMONG
KAMLS PRESENT
VS. KAML ABSENT,
P VALUEa
Among
Female
Patients
Among
Male
Patients Overall
KAML-Absent
Group
KAML-Present
Group
1–5 45 42 26 27 27 33 (61) 12 (92) .05
6–20 100 53 75 74 75 25 (84) 75 (56) .02
21–49 27 63 76 70 74 7 (57) 20 (55) .30
a By x2 analysis.
KAMLs present could favor the demonstration of an
association between IFN-g allele 2 and the absence of
KAMLs, we repeated x2 analysis and included these pa-
tients, as shown in table 6. When we compared 1–20-
year-olds with KAMLs present to 6–20-year-olds with
KAMLs absent, the KAML frequency was 78% (87/
112), and the age distribution was similar in both groups
(P value not significant [NS], by t test). The frequency
of IFN-g allele 2 was 84% in the KAML-absent group
and 61% in the KAML-present group ( , by x2Pp .03
analysis). When the older patients were included for
comparison between 1–49-year-olds with KAMLs pres-
ent and 6–34-year-olds with KAMLs absent, the KAML
frequency was 77%, and the age distribution was similar
in both groups (P value NS, by t test). Including the
older patients, the frequency of IFN-g allele 2 was 78%
in the KAML-absent group and 59% in the KAML-
present group ( , by x2 analysis). This data dem-Pp .06
onstrates that the association between IFN-g allele 2 is
statistically significant in the 1–20-year-old group
( ) and approaches statistical significance in thePp .03
1–49-year-old group ( ).Pp .06
Association between IFN-g Allele 2 and Absence
of KAMLs Is Evident in Males but Not in Females
We also considered the possibility that gender is an
important variable in the association between IFN-g al-
lele 2 and the absence of KAMLs. Here we will focus
on the 6–49-year-old group and the 6–20-year-old
group. The ratio of female:male patients in these age
groups was close to 50%, and the KAML frequency
(∼75%) is similar in male and female patients (tables 1
and 5). The frequency of IFN-g allele 2 is similar in male
and female patients in the KAML-present group. How-
ever, in the KAML-absent group, the frequency of IFN-
g allele 2 is higher in male patients than in female pa-
tients (table 7). Furthermore, in the 6–20-year-old group,
there is evidence for significant association between IFN-
g allele 2 and the absence of KAMLs in male patients
( , by Fisher test) but not in female patientsPp .006
( [NS], by Fisher test). In the 6–49-year-oldPp .52
group, there was a trend toward a significant association
in male patients ( , by Fisher test) but not inPp .06
female patients ( ). Because there is evidence thatPp .28
these age groups are associated when male and female
patients are combined, it is possible that there is aweaker
association in female patients that could not be dem-
onstrated by this relatively small study.
TDT Suggests That IFN-g Allele 2 Is Associated
with Reduced Frequency of KAMLs
We also applied TDT to this set of patients, to confirm
the association between IFN-g allele 2 and the absence
of KAMLs. In the present analysis, we included a subset
of the same 127 patients (ages 6–49 years) for whom
parental DNA samples were available for IFN-g geno-
typing. Of the 190 parents of patients with KAMLs, 111
(58%) were genotyped for the IFN-g polymorphism,
yielding information on transmission or nontransmis-
sion of allele 2 in 35 of the 95 patients (37%). Of the
64 parents of patients with no KAMLs, 22 (34%) of
were genotyped, yielding information on transmission
in 11 of the 32 patients (34%). The TDT data are sum-
marized in table 8. Analysis of all informative cases
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Table 6
IFN-g Allele Frequencies in TSC2 Patients Including 1–5-Year-Olds with
KAMLs Present
All
KAML
Absent
KAML
Present P
Age 120 years excluded:
N (%) 112 25 (22) 87 (78)
Mean age (range) [in years] 11.5 (6–20) 10.7 (1–20) .42a
No. (%) with allele 2 present 21 (84) 53 (61) .03b
No. (%) with allele 2 absent 4 (14) 34 (39)
Age 120 years included:
N (%) 139 32 (23) 107 (77)
Mean age (range) [in years] 14.1 (6–34) 14.3 (1–49) .89c
No. (%) with allele 2 present 25 (78) 64 (59) .06d
No. (%) with allele 2 absent 7 (22) 43 (41)
a By t test; result not significant.
b By x2analysis.
c By t test; result not significant.
d By x2analysis.
Table 7
IFN-g Allele 2 Frequencies in Male and Female Patients
SUBGROUPS
BY AGE (IN
YEARS) AND
SEX
NO. (% WITH ALLELE 2
PRESENT) AMONG
KAML PRESENT
VS. KAML ABSENT,
P VALUEa
KAML-Absent
Group
KAML-Present
Group
6–49:
M 15 (87) 42 (57) .06
F 17 (71) 53 (55) .28
Overall 32 (78) 95 (56) .03
6–20:
M 12 (100) 35 (57) .005
F 13 (69) 40 (55) .52
Overall 25 (84) 75 (56) .02
21–49:
M 3 (33) 7 (57) 1.99
F 4 (75) 13 (54) .60
Overall 7 (57) 20 (55) 1.99
a By Fisher test.
shows that, among TSC2 patients with KAMLs present,
allele 2 was transmitted in 17 (40%) and was not trans-
mitted in another 26 (60%) (TDT ;2x p 1.88 Pp
). Among TSC2 patients with KAMLs absent, allele.170
2 was transmitted in 12 (75%) and was not transmitted
in 4 (25%) (TDT ; ). If we combine2x p 4.0 Pp .045
the data from the KAML-present and KAML-absent
groups for these TSC2 patients, then we can calculate a
more significant combined TDT x2 value (Spielman et
al. 1993). The combined TDT x2 value increases to 4.90,
with a more significant P value of .027. Because several
investigators (Curtis and Sham 1995; Ewens and Spiel-
man 1999; Knapp 1999) have described certain biases
in the TDT if incomplete data are included, we repeated
the TDT calculation and excluded single-parent cases
that, according to Ewens and Spielman (1999), may in-
troduce bias. The resulting TDT statistic was 5.45
( ). These findings agree with the standard x2P ! .020
analysis (table 1) and support our conclusion that there
is an association between IFN-g allele 2 and the absence
of KAML development in TSC2 patients.
Discussion
The high degree of variability of TSC clinical manifes-
tations, including those among related and unrelated pa-
tients with the same mutation (Smalley et al. 1994; Da-
bora et al. 2001), suggests the possibility that modifier
genes influence disease severity. In the present study, we
have examined the relationship between the severity of
renal disease and alleles of an IFN-g microsatellite in pa-
tients with TSC. This is the first study to show that genetic
modifiers may influence the TSC clinical phenotype.
We found an association between IFN-g allele 2 and
the absence of KAMLs in TSC2 patients. This finding
suggests that IFN-g allele 2 may be a genetic modifier
that reduces KAML development or growth. Although
this is a relatively small study, the association between
IFN-g allele 2 and the decreased frequency of KAMLs
was demonstrated using two independent statistical ap-
proaches, strengthening the conclusion that there is a
true association. We also showed that the distribution
of TSC2 mutation types in the KAML-present group is
similar to that in the KAML-absent group, eliminating
the possibility that mutation type is a significant con-
founding variable. Because allele 2 has been shown to
be associated with a higher level of IFN-g expression
in mitogen-stimulated mononuclear cells in vitro (Prav-
ica et al. 1999), it is plausible that the association re-
ported here is due to a reduction in KAML development
in the presence of higher levels of IFN-g.
Because both age and gender are known variables that
influence the expression of a variety of TSC manifes-
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Table 8
TDT for IFN-g Allele 2 and KAML in TSC2 Disease
GROUP
NO. (%) OF ALLELES
TRANSMITTED WHEN
IFN-g ALLELE 2 IS
PROBAND
NUMBER TDT x2 PTransmitted Not Transmitted
All informative cases:
TSC2 and KAMLs present:
Observed 17 (40) 26 (60) 35 1.88 .17
Expected 21.5 (50) 21.5 (50)
TSC2 and KAMLs absent:
Observed 12 (75) 4 (25) 11 4 .045
Expected 8 (50) 8 (50)
Combined:
Affected (KAMLs present) 17 (40) 26 (60) 35 4.9 .027
Unaffected (KAMLs absent) 12 (75) 4 (25) 11
One-parent cases with potential bias excluded:a
Affected (KAMLs present) 14 (38) 23 (62) 30 5.45 .02
Unaffected (KAMLs absent) 12 (75) 4 (25) 11
a Combined.
tations, we did subgroup analyses, to investigate the
impact that age and gender have in the present study.
We initially used an age cutoff of 15 years, because we
wished to exclude the youngest age group with a rel-
atively low frequency of KAMLs. When we divided our
entire cohort into three age groupings (1–5 years, 6–20
years, and 21–49 years), we found evidence of an as-
sociation between IFN-g allele 2 and the absence of
KAMLs in the 6–20-year-old group ( ) but notPp .02
in the others (table 5). In the 21–49-year-old group, the
frequency of IFN-g allele 2 was similar in the KAML-
absent and KAML-present groups. In the 1–5-year-old
group there was an unexpected finding of a very high
frequency of IFN-g allele 2 in the KAML-present group
(11 of 12 patients [92%]) compared with a frequency
of 61% in the KAML-absent group. We considered the
possibility that this group might have a different mu-
tation spectrum, so we investigated this and found a
spectrum similar to that of the remainder of the cohort
(data not shown). The observation seems likely to have
been the result of random chance in a small subgroup
of 12 patients. To eliminate potential bias introduced
by excluding 1–5-year-olds with KAMLs present, we
repeated the x2 analysis in two age groups that include
these cases. As shown in table 6, there is evidence for
significant association between IFN-g allele 2 and the
absence of KAMLs in the 1–20-year-old group (Pp
), and there is a trend toward significant association.03
in the 1–49-year-old group ( ). These results sup-Pp .06
port the conclusion that the unexpected high frequency
of IFN-g allele 2 in the group of 1–5-year-olds with
KAMLs present is due to random chance in a small
subgroup.
Although there are no obvious gender differences in
the neurologic and skin manifestations of TSC, some
studies suggest that sex differences do exist in lung and
kidney lesions. Many reports describe lymphangioleio-
myomatosis (LAM) in a small percentage of young
women with TSC (Gomez et al. 1999). The prevalence
of LAM in young women with TSC increases to
34%–39% if high-resolution CT scanning is used to
screen women without pulmonary symptoms (Franz et
al. 2001; Moss et al. 2001). Gender differences in
KAML growth have also been observed. Although
Ewalt et al. (1998) reported a similar frequency of
KAMLs in male (72%) and female (76%) patients in a
study of 60 children (ages 1–18 years) with TSC, when
the lesions were followed over time, the tendency for
the lesions to grow was higher in female patients than
in male patients, suggesting that female hormones play
a role in KAML progression. This possibility is further
supported by the demonstration of progesterone-recep-
tor immunostaining on a high number of KAMLs in
women (Henske et al. 1998). One more example of
gender differences in TSC comes from a TSC1 mouse
model in which liver hemangiomas are more severe in
female littermates than in male littermates and is as-
sociated with early lethality in the female littermates
(Kwiatkowski et al. 2002). For these reasons, we ana-
lyzed our data according to gender (tables 5 and 7).
Although there is a similar number of male and female
patients with a similar frequency of KAMLs (table 5),
the association between IFN-g allele 2 and the absence
of KAMLs can be demonstrated in male 6–20-year-olds
and 6–49-year-olds but not in female patients of the
same age groups. Because there is evidence of associa-
tion when male and female patients are combined and
also because the frequency of IFN-g allele 2 is higher
in female patients with KAMLs absent than in female
patients with KAMLs present, it is possible that there
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is a weaker association in female patients that could not
be demonstrated in this subgroup analysis. These data
suggest that the factors that contribute to KAML de-
velopment may be different in male and female patients
with TSC. Because the numbers of patients in the gender
subgroups are small, it will be important to verify this
gender analysis in a larger cohort.
Renal disease, primarily the development of KAMLs,
is a significant cause of morbidity and mortality in TSC.
Kidney pathology (renal failure, bleeding, or renal cell
carcinoma) was the cause of death in 31% (11/36) pa-
tients 110 years old with TSC who died of TSC-related
complications (Shepherd et al. 1991). Although further
investigation is required, this study suggests a potential
role for IFN-g in controlling the development and/or
progression of KAMLs in TSC. Since IFN-g is already
in general clinical use for the treatment of chronic gran-
ulomatous disease (Johnston 2001) and malignant os-
teopetrosis (Key et al. 1995) and has been studied at a
variety of doses in clinical trials for the treatment of
renal cell carcinoma (Aulitzky et al. 1989; Ellerhorst et
al. 1994; Gleave et al. 1998), it could be readily adopted
in clinical trials for KAMLs. Since there is currently no
known medical therapy for treatment of progressive
KAMLs, this is of significant interest. In addition to
suggesting a potential novel treatment for KAMLs, the
present study is the first to demonstrate the presence of
genetic modifiers for manifestations of TSC. Our results
indicate that age and gender may be important variables
that influence the role of modifiers and that they should
be considered in further investigations of modifying fac-
tors and as treatments are developed and tested in TSC.
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